Sigal Charles Elliott

CIK 00016619084 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001661908

Recent Transactions

44 trades

Award
Vir Biotechnology, Inc.$VIR
Stock Option (Right to Buy)
2025-05-30+16,000→ 16,000 total
Award
Vir Biotechnology, Inc.$VIR
Common Stock
2025-05-30+8,000→ 31,806 total
Award
ALNYLAM PHARMACEUTICALS, INC.$ALNY
Common Stock
2025-05-08+775→ 775 total
Award
ALNYLAM PHARMACEUTICALS, INC.$ALNY
Stock Option (right to buy)
2025-05-08+1,558→ 1,558 total
Award
Vir Biotechnology, Inc.$VIR
Stock Option (Right to Buy)
2024-05-30+16,000→ 16,000 total
Award
Vir Biotechnology, Inc.$VIR
Common Stock
2024-05-30+8,000→ 23,806 total
Award
ALNYLAM PHARMACEUTICALS, INC.$ALNY
Stock Option (right to buy)
2024-05-16+5,228→ 5,228 total
Disposition to Issuer
Surface Oncology, Inc.
Common Stock
2023-09-08−45,453→ 0 total
Disposition to Issuer
Surface Oncology, Inc.
Stock Option (Right to Buy)
2023-09-08−113,636→ 0 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2023-07-03+933,317→ 933,317 total
Award
Vir Biotechnology, Inc.$VIR
Common Stock
2023-05-22+6,027→ 15,806 total
Award
Vir Biotechnology, Inc.$VIR
Stock Option (Right to Buy)
2023-05-22+12,054→ 12,054 total
Award
ALNYLAM PHARMACEUTICALS, INC.$ALNY
Stock Option (right to buy)
2023-05-18+3,454→ 3,454 total
Purchase
Vir Biotechnology, Inc.$VIR
Common Stock
2023-03-01$22.73/sh+2,500→ 10,000 total
Purchase
Vir Biotechnology, Inc.$VIR
Common Stock
2023-01-05$24.96/sh+2,500→ 7,500 total
Purchase
Vir Biotechnology, Inc.$VIR
Common Stock
2023-01-04$25.25/sh+2,500→ 5,000 total
Purchase
Vir Biotechnology, Inc.$VIR
Common Stock
2023-01-03$25.60/sh+2,500→ 2,500 total
Award
ALNYLAM PHARMACEUTICALS, INC.$ALNY
Stock Option (right to buy)
2022-08-22+4,456→ 4,456 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2022-07-01+737,050→ 737,050 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2022-06-08+24,000→ 24,000 total
Award
Vir Biotechnology, Inc.$VIR
Stock Option (Right to Buy)
2022-05-23+12,810→ 12,810 total
Award
Vir Biotechnology, Inc.$VIR
Common Stock
2022-05-23+6,405→ 9,779 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2021-07-01+474,385→ 474,385 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2021-06-08+17,700→ 17,700 total
Award
Vir Biotechnology, Inc.$VIR
Stock Option (Right to Buy)
2021-05-21+6,748→ 6,748 total
Award
Vir Biotechnology, Inc.$VIR
Common Stock
2021-05-21+3,374→ 3,374 total
Award
Vir Biotechnology, Inc.$VIR
Stock Option (Right to Buy)
2020-07-10+28,394→ 28,394 total
Award
Vir Biotechnology, Inc.$VIR
Stock Option (Right to Buy)
2020-07-10+57,777→ 57,777 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2020-07-01+184,258→ 184,258 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2020-06-10+12,000→ 12,000 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2019-10-01+13,572→ 13,572 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2019-07-02+234,407→ 234,407 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2019-07-01+5,696→ 5,696 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2019-06-05+12,100→ 12,100 total
Award
Surface Oncology, Inc.
Stock Option (Right to Buy)
2018-07-02+8,882→ 8,882 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2018-06-22+154,809→ 154,809 total
Conversion
Surface Oncology, Inc.
Series A Preferred Stock
2018-04-23−100,000→ 0 total
Conversion
Surface Oncology, Inc.
Common Stock
2018-04-23+45,453→ 45,453 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2017-07-03+220,788→ 220,788 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2016-08-11+184,562→ 184,562 total
Purchase
Adaptimmune Therapeutics PLC$ADAP
Ordinary Shares with a nominal value of GBP0.001 per share
2016-05-19$1.56/sh+15,000→ 314,100 total
Purchase
Adaptimmune Therapeutics PLC$ADAP
Ordinary Shares with a nominal value of GBP0.001 per share
2016-05-18$1.55/sh+15,000→ 299,100 total
Purchase
Adaptimmune Therapeutics PLC$ADAP
Ordinary Shares with a nominal value of GBP0.001 per share
2016-05-17$1.53/sh+15,000→ 284,100 total
Purchase
Adaptimmune Therapeutics PLC$ADAP
Ordinary Shares with a nominal value of GBP0.001 per share
2016-05-16$1.50/sh+15,000→ 269,100 total

Companies

Recent Filings

Address

C/O VIR BIOTECHNOLOGY, INC. 1800 OWENS STREET, SUITE 900

SAN FRANCISCO, CA, 94158

View on SEC.gov